bioMérieux S.A. (FRA:EYWN)

Market Cap	12.37B
Revenue (ttm)	4.12B
Net Income (ttm)	377.90M
Shares Out	n/a
EPS (ttm)	3.17
PE Ratio	32.74
Forward PE	21.56
Dividend	0.90 (0.84%)
Ex-Dividend Date	Jun 9, 2025

Volume	n/a
Average Volume	3
Open	104.80
Previous Close	106.30
Day's Range	104.80 - 104.80
52-Week Range	96.60 - 130.60
Beta	n/a
RSI	43.55
Earnings Date	Mar 4, 2026

About bioMérieux

bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; BACT/ALERT VIRTUO, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction system (PCR); BIOFIRE SPOTFIRE, a lowplex PCR point-of...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 1963
• Employees: 14,754
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: EYWN

Financial Performance

In 2024, bioMérieux's revenue was 3.98 billion, an increase of 8.31% compared to the previous year's 3.67 billion. Earnings were 432.20 million, an increase of 20.86%.